CSL BEHRING RECOMBINANT FACILITY AG has a total of 60 patent applications. It decreased the IP activity by 95.0%. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), China and Brazil. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ARIZEKE PHARMACEUTICALS INC, CSL Behring Lengnau AG and MABXIENCE S A.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 11 | |
#2 | China | 9 | |
#3 | Brazil | 7 | |
#4 | Canada | 7 | |
#5 | Republic of Korea | 7 | |
#6 | Singapore | 6 | |
#7 | United States | 5 | |
#8 | Taiwan | 4 | |
#9 | EPO (European Patent Office) | 2 | |
#10 | Hong Kong | 1 | |
#11 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Pestel Sabine | 31 |
#2 | Schulte Stefan | 29 |
#3 | Weimer Thomas | 25 |
#4 | Panousis Con | 13 |
#5 | Kalina Uwe | 12 |
#6 | Moses Michael | 12 |
#7 | Dickneite Gerhard | 12 |
#8 | Dower Steve | 12 |
#9 | Metzner Hubert | 9 |
#10 | Emmrich Kerstin | 9 |
Publication | Filing date | Title |
---|---|---|
TW201828974A | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
KR20180100701A | Recombinant IgG Fc multimer | |
CA3008448A1 | Mutated von willebrand factor | |
WO2017102794A1 | Method for increasing the heterogeneity of o-glycosylation of recombinant factor vii | |
CA2986626A1 | Truncated von willebrand factor polypeptides for treating hemophilia | |
KR20180012303A | Method for producing modified von Willebrand factor | |
KR20170125942A | Compound for improving half-life of von Willebrand factor |